Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the american cancer society trial Academic Article Article uri icon


MeSH Major

  • Heart Ventricles
  • Purkinje Fibers
  • Signal Processing, Computer-Assisted


  • Forty-nine patients with non-Hodgkin's lymphoma or Hodgkin's disease were entered into a multi-institutional phase II trial to evaluate the antitumor activity of human interferon alpha, prepared from buffy coats. Interferon alpha was administered intramuscularly in doses of 1 X 10(6) u, 3 X 10(6) u or 9 X 10(6) u daily for 30 days. Objective partial responses were seen in 3 of 18 patients with nodular lymphoma, all at the 9 X 10(6) u dose. Interferon alpha was not observed to be of therapeutic benefit in the other subtypes of non-Hodgkin's lymphoma or Hodgkin's disease. The major toxicities consisted of fatigue, fever, myalgias and weight loss. Serum interferon levels obtained 3 to 4 hours after injection varied widely, even among patients treated at the same dose level. Despite the relatively low doses of interferon used and the brief period of administration, this study extends the earlier observations of the antitumor effect of interferon in nodular lymphoma. These results are discussed in relation to the cumulative experience in human lymphoma using alpha interferons induced in human leukocytes and those produced in bacteria by recombinant DNA techniques.

publication date

  • January 1985



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19850915)56:6<1305::AID-CNCR2820560614>3.0.CO;2-N

PubMed ID

  • 4027869

Additional Document Info

start page

  • 1305

end page

  • 10


  • 56


  • 6